I completed my undergraduate degree in Molecular and Cellular Biochemistry at the University of Oxford, before working in the Callaghan Cancer Research group at the John Radcliffe Hospital investigating the structural properties of the P-glycoprotein multi-drug transporter. I then completed my DPhil studies at the Weatherall Institute of Molecular Medicine in the Arthritis Research group headed by Paul Bowness, investigating the link between HLA-B27 and Spondyloarthritis, and continued this project as a post-doc at the Botnar Research Centre. The primary focus of this research was to characterise the expression of potentially pathogenic non-conventional forms of B27 in the context of a disease setting using novel B27-specific monoclonal antibodies.
At the Jenner institute, I am currently working on the development of novel therapeutic interventions for the treatment of haematological disorders - non-transfusion-dependent thalassemia (NTDT) and anaemia of inflammation - which involves generating recombinant proteins and monoclonal antibodies for subsequent characterisation and functional testing.
Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia
Arezes J. et al, (2020), Blood, 135, 547 - 557
Salmonella exploits HLA-B27 and host unfolded protein responses to promote intracellular replication
Antoniou AN. et al, (2019), Annals of the Rheumatic Diseases, 78, 74 - 82
Erythroferrone inhibits the induction of hepcidin by BMP6
Arezes J. et al, (2018), Blood, 132, 1473 - 1477
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3
Pasricha S-R. et al, (2017), Nature Communications, 8
Polymorphisms in the F Pocket of HLA-B27 Subtypes Strongly Affect Assembly, Chaperone Interactions, and Heavy-Chain Misfolding
Guiliano DB. et al, (2017), Arthritis & Rheumatology, 69, 610 - 621